REGULATION OF GENE-BASED COGNITIVE MODIFICATION: LEGAL FRAMEWORK AND CASE LAWS

1. INTRODUCTION

Gene-based cognitive modification refers to the use of genetic engineering, gene editing, gene therapy, or gene-regulation techniques intended to influence cognitive abilities such as memory, learning, attention, or information processing. Technologies such as CRISPR-Cas systems may eventually offer ways to investigate or modify biological pathways associated with neurological function. However, cognitive abilities are influenced by numerous genes, environmental conditions, development, and complex biological interactions. No simple genetic intervention can reliably guarantee enhanced intelligence.

The distinction between treatment and enhancement is legally important. Gene therapy intended to treat a serious neurological disorder may be evaluated under established medical and clinical-research frameworks. By contrast, modifying the genetic characteristics of a healthy person to improve cognitive performance raises additional concerns about safety, consent, social inequality, genetic discrimination, and effects on future generations.

In India, no single statute comprehensively regulates gene-based cognitive enhancement. The relevant framework includes the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, the National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, applicable biosafety requirements, and constitutional protections.

2. LEGAL AND REGULATORY FRAMEWORK

A. GENE THERAPY AND CLINICAL-TRIAL REGULATION

Gene therapy products are regulated through the applicable drug regulatory framework. The Central Drugs Standard Control Organisation (CDSCO) oversees relevant approvals, while institutional ethics committees assess human-research protocols. The 2019 national gene therapy guidelines address product quality, preclinical evaluation, clinical-trial design, safety, efficacy, and long-term follow-up. These requirements are particularly important where genetic interventions may produce persistent or irreversible biological effects. <Cite refs={["turn430740search12","turn430740search1"]}/>

The regulatory route depends on the intervention, intended medical purpose, product classification, and proposed use. Approval of a gene therapy for a particular disease does not automatically authorise its use to enhance cognition in healthy individuals.

B. GERM-LINE AND SOMATIC MODIFICATION

Somatic gene modification affects cells of the treated individual and is not ordinarily transmitted to descendants. Germ-line modification affects reproductive cells or embryos and may transmit changes to future generations.

India's National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, prohibit germ-line gene therapy. Consequently, heritable cognitive enhancement cannot be treated as an ordinary permissible clinical application under that framework. The precise legal consequences of particular research activities must also be assessed under applicable legislation and ethical guidelines. <Cite refs={["turn430740search12","turn430740search15"]}/>

C. CONSTITUTIONAL RIGHTS AND ETHICS

Article 14 of the Constitution protects against arbitrary state action, while Article 21 protects life, personal liberty, and dignity. These principles are relevant to bodily integrity, informed consent, and protection against coercive experimentation.

The Indian Council of Medical Research's ethical guidelines also emphasise risk minimisation, privacy, professional competence, accountability, and the protection of research participants.

3. IMPORTANT CASE LAWS

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) 10 SCC 1

Authority: Direct authority on constitutional privacy; analogous to genetic modification.

The Supreme Court recognised privacy as a fundamental right, including interests in personal autonomy and informational privacy.

Application: Genetic information and decisions concerning genetic interventions implicate personal autonomy and privacy. State interference or collection of genetic information must satisfy applicable constitutional and legal requirements.

2. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Authority: Direct authority on informed consent in medical treatment; analogous to gene editing.

The Supreme Court held that valid medical consent requires adequate information and authorisation for the proposed intervention.

Application: Participants in gene-editing research must receive appropriate information about material risks, uncertainties, alternatives, and the experimental nature of the intervention. Consent to ordinary treatment does not automatically authorise a substantially different experimental procedure.

3. Common Cause v. Union of India (2018) 5 SCC 1

Authority: Direct authority on dignity and medical autonomy; analogous to genetic enhancement.

The Supreme Court recognised autonomy and dignity in the context of end-of-life decision-making.

Application: The decision supports respect for personal autonomy in medical matters. However, individual consent alone cannot override regulatory prohibitions or make an otherwise unlawful genetic intervention permissible.

4. A.P. Pollution Control Board v. Prof. M.V. Nayudu (Retd.) (1999) 2 SCC 718

Authority: Direct authority on scientific uncertainty and expert assessment; analogous to human gene modification.

The Supreme Court highlighted the importance of scientific expertise in decisions involving complex technical questions and uncertain risks.

Application: Gene-based cognitive modification should be assessed using appropriate scientific evidence, expert review, and careful risk evaluation rather than speculative claims about enhanced intelligence.

5. N.D. Jayal v. Union of India (2004) 9 SCC 362

Authority: Direct authority on judicial review of technically complex public decisions; analogous to genetic regulation.

The Supreme Court considered judicial review in the context of a major development project involving technical and environmental concerns.

Application: Courts generally respect competent technical assessment but may examine legality, procedural fairness, and whether relevant risks were properly considered.

6. Suchita Srivastava v. Chandigarh Administration (2009) 9 SCC 1

Authority: Direct authority on reproductive autonomy; analogous to heritable genetic modification.

The Supreme Court recognised reproductive choice as an aspect of personal liberty under Article 21.

Application: The judgment is relevant to debates about reproductive autonomy and genetic intervention. It does not, however, establish a right to undertake germ-line editing contrary to applicable regulatory restrictions.

7. Yash Charitable Trust v. Union of India, 2026 INSC 96

Authority: Direct authority on experimental stem-cell interventions; analogous to gene-based cognitive modification.

In its judgment dated 30 January 2026, the Supreme Court addressed the use of unproven stem-cell interventions as routine clinical services and emphasised compliance with the applicable regulatory framework.

Application: The decision reinforces the principle that experimental biological interventions cannot be marketed as established clinical treatments without the necessary scientific and regulatory basis. It concerns stem-cell therapy, not gene-based cognitive enhancement directly. <Cite refs={["turn430740search2"]}/>

4. PRINCIPAL REGULATORY CHALLENGES

A. SAFETY AND REVERSIBILITY: Genetic interventions may produce unintended effects, persistent biological changes, or long-term consequences that cannot be readily reversed.

B. HERITABLE CONSEQUENCES: Germ-line modification raises concerns for future generations, who cannot provide consent to the intervention.

C. INFORMED CONSENT: Participants must understand uncertainties, potential harms, and the distinction between established treatment and experimental enhancement.

D. EQUALITY AND DISCRIMINATION: Enhancement technologies could increase inequality or create pressure on individuals to undergo genetic modification to compete academically or professionally.

E. PRIVACY: Genetic information must be protected against unauthorised disclosure and misuse, including discriminatory treatment.

5. PRACTICAL COMPLIANCE REQUIREMENTS

Researchers and healthcare institutions should:

Determine the intervention's legal classification and intended purpose.

Obtain all applicable regulatory permissions and ethics committee approvals before human research.

Comply with the relevant gene therapy guidelines and biosafety requirements.

Obtain valid informed consent and provide appropriate information about risks and uncertainties.

Establish long-term safety monitoring where required.

Protect genetic information and maintain secure research records.

Avoid unsupported claims that genetic modification can reliably enhance intelligence.

Refrain from prohibited germ-line interventions and assess any proposed reproductive research under the applicable legal framework.

6. CONCLUSION

Gene-based cognitive modification raises complex questions concerning scientific safety, personal autonomy, equality, and intergenerational responsibility. India's existing framework permits the development of appropriately regulated gene therapies for lawful medical purposes but does not establish a general authorisation for cognitive enhancement. The 2019 national gene therapy guidelines specifically prohibit germ-line gene therapy.

The judgments in Puttaswamy, Samira Kohli, Common Cause, A.P. Pollution Control Board, N.D. Jayal, Suchita Srivastava, and Yash Charitable Trust provide relevant constitutional, ethical, and regulatory principles. None directly decides the legality of gene-based cognitive enhancement. Accordingly, lawful development requires compliance with applicable regulatory permissions, scientific evidence requirements, informed-consent standards, and restrictions on heritable modification. Responsible governance must distinguish therapeutic innovation from enhancement claims and prevent unproven or prohibited interventions from being offered as established medical practice.